Clinical trial

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

NCT06848426

Study summary

ClinicalTrials.gov

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Xingbaiji Formula Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-03-10

PhaseNA

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Non-small Cell Lung Cancer Recurrentunresolved

Non-small Cell Lung Cancer Stage IIIBunresolved

Non-small Cell Lung Cancer Stage IVunresolved

Non-small Cell Lung Cancer Metastaticunresolved

Interventions

Xingbaiji FormulaDRUG

Sponsors & collaborators

Jiangxi Provincial People's Hopitallead sponsor

Mapped research locations

NanchangJiangxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06848426 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.